41 results
8-K
EX-10.1
LXRX
Lexicon Pharmaceuticals Inc
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
than those specifically set forth herein or in the Engagement Letters between the Company and the Placement Agents (the “Engagement Letters”); (ii … ) be indemnified by the Company for acting as the Placement Agents hereunder pursuant the indemnification provisions set forth in the Engagement Letters
8-K
EX-1.1
LXRX
Lexicon Pharmaceuticals Inc
2 Jun 23
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
4:31pm
engagement of the Underwriters in connection with the offering and the process leading up to the offering is as independent contractors and not in any
424B5
LXRX
Lexicon Pharmaceuticals Inc
1 Jun 23
Prospectus supplement for primary offering
9:08pm
based on the number of heart failure lives, and we have tailored those efforts by deploying unique engagement strategies for the messages we think
8-K
y23aejen8cfi3
31 May 23
Lexicon Announces Proposed Public Offering of Common Stock
4:17pm
424B5
sehw15
31 May 23
Prospectus supplement for primary offering
4:07pm
8-K
EX-1.1
fkxztc92xxb7vpc5kif
29 Jul 22
Lexicon Announces Proposed Public Offering of Common Stock
5:18pm
8-K
EX-99.1
3u3wf0gkay51 8lw
3 Nov 21
Lexicon Pharmaceuticals Reports Third Quarter 2021
4:05pm
8-K
EX-99.2
vx2jvc0rxemwlqnol6
2 Aug 21
Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
7:20am
8-K
EX-2.1
ohs vymc8y7
11 Sep 20
Lexicon Pharmaceuticals Completes the Sale of Xermelo to
4:11pm